Development of a risk score to guide targeted hepatitis C testing among human immunodeficiency virus patients in Cambodia

Table 3 Crude and adjusted likelihood ratios of the candidate predictors for hepatitis C virus coinfection

Predictor variables after dichotomization	Number of HIV patients	Outcome events, n (%)	Crude likelihood ratios (LHR)		Adjusted likelihood ratios (aLHR)
			Positive LHR	Negative LHR	Positive aLHR	Negative aLHR
Male gender	1307	45 (3.4)	0.99	1.01	-	-
Age ≥ 50 years	601	45 (7.5)	2.55	0.71	2.18	0.72
Platelets < 200 × 109 cells/L	442	49 (11.1)	3.46	0.62	1.69	0.82
AST ≥ 30 IU/L	1190	88 (7.4)	2.21	0.28	1.48	0.53
ALT ≥ 40 IU/L	887	69 (7.8)	2.33	0.49	-	-
APRI ≥ 0.45	633	78 (12.3)	3.88	0.33	2.42	0.48
Having diabetes	113	13 (11.5)	3.76	0.90	2.14	0.94
Presenting fatigue OR myalgia/arthralgia OR anorexia/weight loss	301	21 (7.0)	2.11	0.88	-	-
Generalized pruritus	120	10 (8.3)	2.61	0.94	2.04	0.95
Having a partner OR household member with liver disease	185	10 (10.3)	3.21	0.87	3.62	0.85
Poor CD4 recovery on ART	117	5 (4.3)	1.34	0.99	-	-

In bold the adjusted likelihood ratios ≥ 1.5 or ≤ 0.67. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; APRI: AST-to-platelet ratio index; ART: Antiretroviral therapy; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus.